Global Markets Direct is a cutting-edge provider of market research and business consultancies for a wide range of customers worldwide.
A team of analytics is capable to produce all sorts of market information and carry out extensive industry research using unique data and reliable sources to let customers know who they are at the market. Global Markets Direct has profound analytical experience in researching the industries and preparing customized reports across many specific fields.
The company is distinguished by its high-quality consulting products and close inspection of the issues under study. Diligent efforts of the experts make every piece of business information an exclusive source of feasible solutions and valuable advice.
With a commitment to serve every client need, Global Markets Direct collects and interprets the materials for the analysis, uses methods of primary and secondary research and develops one of a kind data packages for global clients. They are able to cover the tones of industry-related information to assist customers in taking the right business decisions and developing their strategic plans.
Under the supervision of skillful managers and experts, business analysts produce reports that include:
- Product portfolio
- Potentially strong market reviews
- Competitive analytics
- Prospect partners
- Mergers and acquisitions project data
- Latest trends across a particular industry area
- Research and development strategies
- The analysis of new customers
- A set of remedial measures for projects
They will search for new partners and highlight the current business issues plus develop new strategies and tactical steps to help you take the lead in the industry where you operate.
Publications found:
2,176
Sort by:
Migraine - Pipeline Review, H2 2020
US$ 2,000.00
... . The Migraine (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Migraine and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
November 2020
342 pages
Type 2 Diabetes - Pipeline Review, H2 2020
US$ 2,500.00
... . The Type 2 Diabetes (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type 2 Diabetes and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
November 2020
1251 pages
Non-Hodgkin Lymphoma - Pipeline Review, H2 2020
US$ 2,500.00
... releases. The Non-Hodgkin Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Non-Hodgkin Lymphoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
November 2020
3999 pages
Schizophrenia - Pipeline Review, H2 2020
US$ 2,000.00
... . The Schizophrenia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Schizophrenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
November 2020
440 pages
Hepatitis B - Pipeline Review, H2 2020
US$ 2,500.00
... releases. The Hepatitis B (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis B and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
November 2020
575 pages
Systemic Lupus Erythematosus - Pipeline Review, H2 2020
US$ 2,500.00
... releases. The Systemic Lupus Erythematosus (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Lupus Erythematosus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
November 2020
816 pages
Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2020
US$ 2,500.00
... . The Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Amyotrophic Lateral Sclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development ...
November 2020
868 pages
Insomnia - Pipeline Review, H2 2020
US$ 2,000.00
... . The Insomnia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Insomnia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
November 2020
164 pages
Psoriatic Arthritis - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Psoriatic Arthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Psoriatic Arthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
November 2020
355 pages
Melanoma - Pipeline Review, H2 2020
US$ 2,500.00
... releases. The Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
November 2020
3809 pages
Irritable Bowel Syndrome - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Irritable Bowel Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Irritable Bowel Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
November 2020
194 pages
Aspergillosis - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Aspergillosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Aspergillosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
November 2020
196 pages
Cervical Cancer - Pipeline Review, H2 2020
US$ 2,500.00
... releases. The Cervical Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Cervical Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
November 2020
1768 pages
Obesity - Pipeline Review, H2 2020
US$ 2,500.00
... releases. The Obesity (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Obesity and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
November 2020
640 pages
Tuberculosis - Pipeline Review, H2 2020
US$ 2,500.00
... releases. The Tuberculosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tuberculosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
November 2020
419 pages
Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2020
US$ 2,500.00
... . The Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
November 2020
733 pages
Diphtheria - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Diphtheria (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Diphtheria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
November 2020
85 pages
Gouty Arthritis (Gout) - Pipeline Review, H2 2020
US$ 2,000.00
... . The Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Gouty Arthritis (Gout) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
November 2020
139 pages
Cancer Pain - Pipeline Review, H2 2020
US$ 2,000.00
... . The Cancer Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cancer Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
November 2020
154 pages
Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2020
US$ 2,500.00
... releases. The Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
November 2020
1581 pages
Diabetic Foot Ulcers - Pipeline Review, H2 2020
US$ 2,000.00
... . The Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Foot Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
November 2020
190 pages
Diabetic Neuropathy - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Diabetic Neuropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
November 2020
143 pages
Diabetic Retinopathy - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Diabetic Retinopathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Retinopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
November 2020
358 pages
Hypercholesterolemia - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Hypercholesterolemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypercholesterolemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
November 2020
269 pages
Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Leishmaniasis (Kala-Azar) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Leishmaniasis (Kala-Azar) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
November 2020
146 pages
Malaria - Pipeline Review, H2 2020
US$ 2,500.00
... releases. The Malaria (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Malaria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
November 2020
407 pages
Herpes Labialis (Oral Herpes) - Pipeline Review, H2 2020
US$ 2,000.00
... . The Herpes Labialis (Oral Herpes) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Herpes Labialis (Oral Herpes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
November 2020
68 pages
Muscular Dystrophy - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Muscular Dystrophy (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
November 2020
287 pages
Anaplastic Astrocytoma - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Anaplastic Astrocytoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Anaplastic Astrocytoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
November 2020
251 pages
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Ankylosing Spondylitis (Bekhterev's Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development ...
November 2020
282 pages
Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2020
US$ 2,000.00
... . The Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Cytomegalovirus (HHV-5) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
November 2020
200 pages
Endometrial Cancer - Pipeline Review, H2 2020
US$ 2,500.00
... releases. The Endometrial Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Endometrial Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
November 2020
1759 pages
Ewing Sarcoma - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Ewing Sarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ewing Sarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
November 2020
829 pages
Neuroblastoma - Pipeline Review, H2 2020
US$ 2,500.00
... releases. The Neuroblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Neuroblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
November 2020
1084 pages
Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2020
US$ 2,000.00
... . The Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Respiratory Syncytial Virus (RSV) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
November 2020
319 pages
Spinal Cord Injury - Pipeline Review, H2 2020
US$ 2,000.00
... . The Spinal Cord Injury (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Spinal Cord Injury and features dormant and discontinued projects. The guide covers therapeutics under Development ...
November 2020
264 pages
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H2 2020
US$ 2,000.00
... The Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Vancomycin-Resistant Enterococcus faecium Infections and features dormant and discontinued projects. The guide covers therapeutics under Development ...
November 2020
108 pages
Benign Prostatic Hyperplasia - Pipeline Review, H2 2020
US$ 2,000.00
... . The Benign Prostatic Hyperplasia (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Benign Prostatic Hyperplasia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
November 2020
129 pages
Escherichia coli Infections - Pipeline Review, H2 2020
US$ 2,000.00
... . The Escherichia coli Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Escherichia coli Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
November 2020
200 pages
Osteonecrosis - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Osteonecrosis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteonecrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
November 2020
35 pages
Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H2 2020
US$ 2,000.00
... . The Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Burkholderia pseudomallei Infections (Melioidosis) and features dormant and discontinued projects. The guide covers therapeutics under Development ...
November 2020
48 pages
Cryptosporidiosis - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Cryptosporidiosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Cryptosporidiosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
November 2020
37 pages
Gliosarcoma - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Gliosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gliosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
November 2020
423 pages
Glycoprotein 41 (gp41) - Pipeline Review, H2 2020
US$ 3,500.00
... and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Glycoprotein 41 (gp41) development landscape Develop and design in-licensing and ...
November 2020
65 pages
Systemic Mastocytosis - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Systemic Mastocytosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Systemic Mastocytosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
November 2020
203 pages
Hypoparathyroidism - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Hypoparathyroidism (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypoparathyroidism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
November 2020
75 pages
Lung Transplant Rejection - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Lung Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Lung Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
November 2020
102 pages
Pemphigus Vulgaris - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Pemphigus Vulgaris (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Pemphigus Vulgaris and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
November 2020
102 pages
